ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

Slides:

Advertisements

Similar presentations

Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.

Advertisements

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients Natalia Sutiman, BSc, Shao.

Journal of Thoracic Oncology Volume 11, Issue 4, Pages (April 2016)

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience Ramsey Asmar, MD, Joshua R. Sonett, MD,

SC09.04 Radiotherapy in China

P3.02b-029 Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 - Prevalence and Treatment Results in Slovakian NSCLC Patients Peter Berzinec,

P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations Ee Ke, Zhihong.

NA Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Circulating tumor DNA: Solid data from liquid biopsies

Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S

PUB023 Effectiveness of Three-Dimensional Video System in Single Port Thorascopic Major Pulmonary Resection: Propensity Score Matched Analysis Hyun Koo.

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables Timothy Edwards, Charlene.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Confessions of a journal junkie

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

P SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial Yenting Ngai,

P3.02b-125 Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer Feliciano Barron, Laura-Alejandra.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients Tao Jiang, Shengxiang.

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Benjamin Besse, Johan.

Support Your Specialty

PS02.17 A Biomarker-Driven Algorithm for Sequencing of Systemic Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Survey of 25 Investigators

P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations Christina Baik,

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

P Accuracy of Combined Semantic and Computational CT Features in Predicting Non-Small Cell Lung Cancer Subtype Usman Bashir, Andrea Bille, Levon.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

ES Lung Cancer Surgery for High Risk Patients

P Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Nicola.

MTP13-01: Indications and limitations of bronchoscopy

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC Chanchai Charonpongsuntorn,

P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403 Sarah Goldberg, James.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

M. Kusumoto Journal of Thoracic Oncology

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

OA07.06 In Early-Stage Lung Adenocarcinomas, Survival by Tumor Size (T) is Further Stratified by Tumor Spread through Air Spaces Takashi Eguchi, Koji.

In This Issue Journal of Thoracic Oncology

Table of Contents Journal of Thoracic Oncology

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

P Impact of Systematic EBUS-TBNA Mediastinal Staging on Radical Radiotherapy Planning in NSCLC N. Hardcastle, A. Cole, G. Turgeon, R. Thomas,

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

P Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI Y. Zhang, Q. Zhou,

P2.03b-002 Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer Xiaorong Dong, Ruiguang Zhang, Xican.

PS01.07 The Clinical Necessity of Extended Thymectomy for Thymic Squamous Cell Carcinomas Revealed by Exome Sequencing J. Jiang, Y. Zhang, C. Jin, J.

3A.01 Efficacy of Programmatic Combined Stereotactic Ablative Radiotherapy and Anti- PD-1 Therapy in Advanced Lung Cancer: A Retrospective Analysis A.

IASLC 6th Latin American Conference on Lung Cancer

PS01.37: Comparison Between Sanger Sequencing and ARMS qPCR Method for EGFR Gene Mutation Detection of Non–Small Cell Lung Cancer Jiexia Zhang, Xiaoshun.

P Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial D. Ettinger, O. Arrieta, N. Karaseva,

PUB006 Impact of the New WHO Classification of Thymic Tumors: Cross-Validation of the Prognostic Value in a Single Institution Cohort Mohamed Kamel,

PUB017 Minimally Invasive Lobectomy is Associated with Lower Noncancer Mortality in Elderly: A Propensity-Score Matched Analysis Boris Hristov, Takashi.

P New Clinical T Classification Is Associated with Pathological Stage I Invasive Adenocarcinoma with Solid Histologic Subtype Y. Sawai, J. Nitadori,

OA Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers B. Dholaria,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Induction Therapy For Locally Advanced Thymoma

Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy

Mark A. Socinski, MD Journal of Thoracic Oncology

Y. Lou, R. Manochakian, J. Cochuyt, D. Hodge, S. Ailawadhi

Robert Comis, MD, The Passing of a “Lung Man”

ED04.01 Surgery in Bronchopulmonary Typical and Atypical Carcinoids

Presentation transcript:

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC David R. Gandara, Sanjay Popat, Barbara Melosky Journal of Thoracic Oncology Volume 12, Issue 1, Pages S51-S52 (January 2017) DOI: 10.1016/j.jtho.2016.11.045 Copyright © 2016 Terms and Conditions

Figure 1 Algorithm for management by Progressive Disease Subtyping EGFR-mutated NSCLC. Journal of Thoracic Oncology 2017 12, S51-S52DOI: (10.1016/j.jtho.2016.11.045) Copyright © 2016 Terms and Conditions

Figure 2 Algorithm for Re-Biopsy and/or Plasma cf DNA Analysis In EGFR-mutated NSCLC. Journal of Thoracic Oncology 2017 12, S51-S52DOI: (10.1016/j.jtho.2016.11.045) Copyright © 2016 Terms and Conditions